Fig. 2From: Reduced RBM3 expression is associated with aggressive tumor features in esophageal cancer but not significantly linked to patient outcomeClinical impact of RBM3 immunostaining. Relationship of RBM3 immunostaining with overall survival in EACs (P = 0.212; a) and ESCCs (P = 0.5992; b)Back to article page